Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998449 | 1.00 | OPRL1 (0.51) | OPRL1OPRM1OPRK1OPRD1ALDH1A1 | |
| SCHEMBL1991830 | 0.83 | OPRL1 (0.74) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1991833 | 0.83 | OPRL1 (0.74) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL1991989 | 0.78 | CYP1A2 (0.55) | OPRL1ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1991987 | 0.78 | CYP1A2 (0.55) | OPRL1ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1993040 | 0.77 | CHRM1 (0.59) | OPRM1OPRK1OPRD1ALDH1A1CYP3A4 | |
| SCHEMBL1992677 | 0.76 | CYP1A2 (0.57) | ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1033178 | 0.76 | CYP1A2 (0.57) | ALDH1A1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL303920 | 0.76 | LMNA (0.63) | OPRL1OPRM1OPRK1OPRD1ALDH1A1 | |
| SCHEMBL2707046 | 0.76 | LMNA (0.63) | OPRL1OPRM1OPRK1OPRD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654807-B2 | Toll-like receptor 8 agonists | THE UNIVERSITY OF KANSAS (US) | 2020-05-19 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | THE UNIVERSITY OF KANSAS | 2016-12-01 | — | — | US | disclosed |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS | 2016-06-16 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015095780-A1 | TOLL-LIKE RECEPTOR 8 AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015023958-A1 | TOLL-LIKE RECEPTOR AGONISTS | THE UNIVERSITY OF KANSAS (US) | 2015-02-19 | — | — | WO | disclosed |
| CN-103561736-A | Methods for treating drug-resistant hepatitis C virus infection with a 5,5-fused arylene or heteroarylene hepatitis C virus inhibitor | IDENIX PHARMACEUTICALS INC | 2014-02-05 | — | — | CN | disclosed |
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102822175-A | 5, 5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS INC (US) | 2012-12-12 | — | — | CN | disclosed |
| EP-2513113-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075615-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071352-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | OPRL1 3866/4885OPRM1 1294/4885OPRK1 1517/4885 |
| US-20160166681-A1 | TOLL-LIKE RECEPTOR AGONISTS | TLR1, TLR7, TLR8 | OPRL1 124/4885OPRM1 144/4885OPRK1 310/4885 |
| US-10654807-B2 | Toll-like receptor 8 agonists | TLR8, TLR7, TLR1 | OPRL1 106/4885OPRM1 160/4885OPRK1 295/4885 |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | OPRL1 3866/4885OPRM1 1294/4885OPRK1 1517/4885 |
| US-20160347715-A1 | Toll-Like Receptor 8 Agonists | TLR8, TLR7, TLR1 | OPRL1 106/4885OPRM1 160/4885OPRK1 295/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | OPRL1 124/4885OPRM1 144/4885OPRK1 310/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | OPRL1 4201/4885OPRM1 2641/4885OPRK1 2154/4885 |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, LIPC, LDHB | OPRL1 4589/4885OPRM1 2861/4885OPRK1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.